Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- UC Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed primary malignant glioma, Grade III or IV
- No uncontrolled infection or other active malignancy or chronic systemic immune therapy.
- ECOG performance status < 3.
- Life expectancy > three months.
- Adequate labs
Exclusion Criteria:
- Diagnosis of genetic disorder of fat metabolism.
- Type 2 diabetes diagnosed with a hemoglobin A1C > 6.4
- Allergic to dairy or lactose intolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Modified Atkins Ketogenic Diet
Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
|
Less than 20 grams of carbohydrates per day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of inducing ketosis
Time Frame: 6 weeks
|
Ketosis measured by serum beta-hydroxybuterate
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assessment of progression free survival
Time Frame: 6 months
|
6 months
|
|
Assessment of survival
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Rekha Chaudhary, MD, University of Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UCCI-BRAIN-16-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
NCT01498328CompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed Glioblastoma
-
NCT05375318CompletedGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Mutant
-
NCT06845020Not yet recruitingGlioblastoma | Glioblastoma, Adult | Glioblastoma WHO Grade IV | Glioblastoma (GBM) | Glioblastoma Multiforme of the Brain
-
NCT06146725RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain
-
NCT07346144RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Glioblastoma (GBM) | High Grade Gliomas
-
NCT06283927RecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, Malignant
-
NCT06649851RecruitingMGMT-Methylated Glioblastoma | Glioblastoma (GBM) | Newly Diagnosed Glioblastoma Multiforme
-
NCT07347210Not yet recruiting
-
NCT05864534RecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
-
NCT07605364Not yet recruiting
Clinical Trials on Modified Atkins Ketogenic Diet
-
NCT04530032CompletedTraumatic Brain Injury
-
NCT01278966Completed
-
NCT02521818CompletedMild Cognitive Impairment | Probable Alzheimer's Disease
-
NCT06105762Not yet recruitingDepressive Disorder | Major Depressive Disorder | Depression, Bipolar
-
NCT02694094Active, not recruitingEpilepsy | Coronary Disease | Cardiovascular Disease | Hypercholesterolemia | Heart Disease | Cerebrovascular Disease | Seizure | Carotid Intimal Medial Thickness 1
-
NCT03718247CompletedRelapsing Remitting Multiple Sclerosis
-
NCT04193891TerminatedEpilepsy | Seizures
-
NCT00639730CompletedEpilepsy | Sturge Weber Syndrome